It will be informative to assess if other treatments currently under development, such as α-synuclein antibody therapy, gene-editing therapy or other molecular treatments specific to monogenic forms of PD, also have a beneficial effect on OD. The gene discussed is SNCA; the disease is Parkinson disease.